Prostacyclin stimulated integrin-dependent angiogenic effects of endothelial progenitor cells and mediated potent circulation recovery in ischemic Hind limb model

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 1053-1062

  Aburakawa, Yoko ^a   Kawabe, Jun Ichi ^a   Okada, Motoi ^a   Yamauchi, Atsushi ^a   Asanome, Akira ^a   Kabara, Maki ^a   Matsuki, Motoki ^a   Takehara, Naofumi ^a   Nakagawa, Naoki ^a   Okumura, Shunsuke ^a   Minami, Yoshinori ^a   Mizukami, Yusuke ^a   Yuhki, Koh Ichi ^a   Ushikubi, Fumitaka ^a   Hasebe, Naoyuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Angiogenesis; Endothelial progenitor cells; Hind limb ischemia; Prostacyclin

Indexed keywords

BETA1 INTEGRIN; COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; L SELECTIN; PADGEM PROTEIN; PROSTACYCLIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; LIMB BLOOD FLOW; LIMB ISCHEMIA; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PERICYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL ADHESION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EPOPROSTENOL; HINDLIMB; ISCHEMIA; MALE; MICE; MICE, KNOCKOUT; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; PERICYTES; RECEPTORS, PROSTAGLANDIN; STEM CELLS;

EID: 84875543426     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0897     Document Type: Article

References (33)

1. Kawabe J, Ushikubi F, Hasebe N. Prostacyclin in vascular diseases: Recent insights and future perspectives. Circ J 2010; 74: 836-843.
2. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW, et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: A possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004; 36: 363-370.
3. Miyahara Y, Ohnishi S, Obata H, Ishino K, Sano S, Mori H, et al. Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats. Biochem Biophys Res Commun 2006; 349: 1242-1249.
4. Nakamura K, Sata M, Iwata H, Sakai Y, Hirata Y, Kugiyama K, et al. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin Sci (Lond) 2007; 112: 607-616.
5. Iwata H, Nakamura K, Sumi M, Ninomiya M, Sakai Y, Hirata Y, et al. Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Life Sci 2009; 85: 255-261.
6. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: A double-blind, randomized, multicenter controlled trial: Beraprost et Claudication Intermittente (BERCI) research group. Circulation 2000; 102: 426-431.
7. Nagaya N. Orally active prostacyclin analogue for cardiovascular disease. Int Angiol 2010; 29: 14-18.
8. Otsuka H, Akashi H, Murohara T, Okazaki T, Shintani S, Tayama K, et al. The prostacyclin analog beraprost sodium augments the efficacy of therapeutic angiogenesis induced by autologous bone marrow cells. Ann Vasc Surg 2006; 20: 646-652.
9. Smith OP, Battersby S, Sales KJ, Critchley HO, Jabbour HN. Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor receptor and the extracellular signaling receptor kinase 1/2 pathway. Endocrinology 2006; 147: 1697-1705.
10. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part II: Cell-based therapies. Circulation 2004; 109: 2692-2697.
11. Tongers J, Roncalli JG, Losordo DW. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvasc Res 2010; 79: 200-206.
12. He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res 2008; 103: 80-88.
13. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004; 94: 230-238.
14. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109: 1543-1549.
15. Heil M, Ziegelhoeffer T, Mees B, Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: Bone marrow delivers software not hardware. Circ Res 2004; 94: 573-574.
16. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002; 143: 3207-3210.
17. Kawabe J, Yuhki K, Okada M, Kanno T, Yamauchi A, Tashiro N, et al. Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol 2010; 30: 464-470.
18. Watanabe H, Katoh T, Eiro M, Iwamoto M, Ushikubi F, Narumiya S, et al. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. Circ J 2005; 69: 124-126.
19. Hillebrands JL, Klatter FA, van Dijk WD, Rozing J. Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat Med 2002; 8: 194-195.
20. Korf-Klingebiel M, Kempf T, Sauer T, Brinkmann E, Fischer P, Meyer GP, et al. Bone marrow cells are a rich source of growth factors and cytokines: Implications for cell therapy trials after myocardial infarction. Eur Heart J 2008; 29: 2851-2858.
21. Deb A, Skelding KA, Wang S, Reeder M, Simper D, Caplice NM. Integrin profile and in vivo homing of human smooth muscle progenitor cells. Circulation 2004; 110: 2673-2677.
22. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693.
23. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: Evidence for enhanced resistance against oxidative stress. Blood 2004; 104: 3591-3597.
24. Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the ENOS gene by the stable prostacyclin analogue beraprost is mediated through CAMP-responsive element in vascular endothelial cells: CLOSE link between PGI2 signal and no pathways. Circ Res 2003; 93: 523-530.
25. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-418.
26. Koerselman J, van der Graaf Y, de Jaegere PP, Grobbee DE. Coronary collaterals: An important and underexposed aspect of coronary artery disease. Circulation 2003; 107: 2507-2511.
27. Gaengel K, Genove G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009; 29: 630-638.
28. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007; 100: 204-212.
29. Garmy-Susini B, Jin H, Zhu Y, Sung RJ, Hwang R, Varner J. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J Clin Invest 2005; 115: 1542-1551.
30. Abraham S, Kogata N, Fassler R, Adams RH. Integrin beta1 subunit controls mural cell adhesion, spreading, and blood vessel wall stability. Circ Res 2008; 102: 562-570.
31. Biancone L, Cantaluppi V, Duo D, Deregibus MC, Torre C, Camussi G. Role of l-selectin in the vascular homing of peripheral blood-derived endothelial progenitor cells. J Immunol 2004; 173: 5268-5274.
32. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2006; 26: 1481-1487.
33. Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, et al. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation 2008; 118: 1021-1033.